Pharma BD Deal Intelligence
The $4.9B stock deal that gave J&J full ownership of Remicade—the anti-TNF biologic that peaked at $9B/yr. At the time, Remicade was approved only for Crohn's disease; the real value came from label expansions into RA, psoriasis, and UC that nobody fully priced in.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Johnson & Johnson acquired Centocor in a $4.9 billion stock-for-stock transaction, gaining full ownership of Remicade (infliximab), which had been approved for Crohn's disease in 1998 and later became one of the world's best-selling biologic drugs.
1.5M US cases/yr · $3.0B Global Autoimmune Rx Market (1999)
Autoimmune and inflammatory conditions span rheumatoid arthritis (women 2-3x more affected than men, per NIAMS), psoriasis, IBD, and ankylosing spondylitis, driven by aberrant TNF-alpha signaling. Anti-TNF monoclonal antibodies such as infliximab (Remicade), adalimumab, and etanercept neutralize TNF and became standard biologic therapy after DMARD failure, reshaping outcomes across rheumatology, gastroenterology, and dermatology.
Remicade generated over $7B in annual peak sales and the anti-TNF class became the world's largest drug class exceeding $36B in 2016 sales. J&J's acquisition of Centocor is widely regarded as one of the most successful biopharma acquisitions ever, validating the biologics revolution in autoimmune disease.
J&J completed $4.9B stock-for-stock acquisition of Centocor, gaining full ownership of Remicade (infliximab) for immunology, gastroenterology, and rheumatology indications.
Remicade sales exceeded $2B annually, becoming one of the top-selling biologics globally for autoimmune diseases including rheumatoid arthritis and Crohn's disease.
Remicade faced biosimilar competition from Inflectra and Renflexis, gradually eroding market share after generating over $50B in cumulative revenue for J&J.
One of pharma's most successful M&A deals. Remicade generated over $50B in cumulative revenue, far exceeding the $4.9B price and establishing J&J as an immunology leader.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Centocor Inc. (this deal) | 1999 | $4.9B | 92 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 1999 deals · Johnson & Johnson deals · Gastroenterology deals